Britain and America have signed a important trade agreement that will guarantee no levies on UK drug exports going into the US market.
The Terms of the Pact
As part of the deal, the UK has pledged to increase funding on medicines through the public health system. This move guarantees that duties on these crucial goods will stay at nothing for a timeframe of three years.
This development is in response to recent statements to significantly raise tariffs on patented pharmaceutical products, with figures floated reaching double the cost.
"This agreement with the United Kingdom strengthens the international landscape for innovative medicines and brings much-needed equity to U.S.–U.K. drug exports," a release said.
Commercial Significance
Pharmaceuticals are one of the UK's biggest export categories to the US, which is easily the primary destination for leading UK drugmakers.
Export figures reveal that in the year to the end of last September, the UK shipped medicines valued at £11.1bn to the US. This figure made up 17.4% of all goods exports in that span.
"This agreement protects employment, increases investment and sets the stage for the UK to become a global hub for biotech and pharma," the Business and Trade Secretary stated.
Specific NHS Changes
The pact entails several specific changes from the UK:
- Revised Affordability Limit: The UK will increase the price threshold at which it considers new medicines to be unaffordable by a quarter.
- Increased NHS Spending: There is a target to increase total public funding on drugs from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Payback Limit: The percentage manufacturers must pay back to the NHS to stay within budget will be limited at fifteen percent. Previously, rebates topped twenty percent.
Industry Background
The deal follows a protracted tension between the sector and the British authorities over spending levels and NHS adoption.
The disagreement were intensified by claims that US consumers were paying a premium for the same drugs than patients in the Britain and the EU.
Over the last 18 months, several large pharmaceutical investments in the UK have been delayed or scrapped, while multi-billion-dollar expansions have been directed toward American operations.
One official stated that the NHS must spend more on drugs, noting that its spending on drugs had shrunk as a share of its total funding over the previous ten-year period.
